Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NexStar Pharm(NXTR) -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (288)	5/30/1998 7:21:00 PM
From: tnsaf	Read Replies (1) \| Respond to of 328

Hi Miljenko, Is it possible that concern about competition for AmBisome may be keeping the price down? Below is an excerpt from this link: biz.yahoo.com Dr. David Denning of the University of Manchester, UK said, ''Our comparison of in vitro activity of NYOTRAN against Aspergillus species with those of other commercially available products indicated that NYOTRAN was fungicidal for 34% of the isolates compared with 7% for AmBisome, 5% for Abelcet and 17% for Amphotec. Aspergillus is a clinically significant filamentous fungus that is known to be difficult to treat in humans with current therapy. We believe NYOTRAN's emerging profile of good antifungal activity against resistant strains as exhibited in the presentations at ECMM may signify potential for use in the hospital environment.'' Jason